New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
13:00 EDTYRCW, CHTP, ICPT, HTH, SHLD, SWS, TGTOn The Fly: Midday Wrap
Stocks on Wall Street were lower at midday after a report showed that U.S. hiring slowed markedly in December. The averages began the session in positive territory, as a "bad news is good news" attitude appeared to breifly return to the market, but the market never gained upside momentum. The averages crossed into negative territory before the end of the first hour of trading and have drifted in negative ground since then. ECONOMIC EVENTS: In the U.S., employers added 74K jobs in December, which was the smallest jobs gain since January 2011 and fell well short of expectations for 200K jobs to have been added. The unemployment rate unexpectedly fell to 6.7% from 7% in November, but the drop occurred largely because more people stopped looking for work. In China, the nation's trade surplus of $25.6B for December was below the $32.2B surplus expected. Export growth of 4.3% was slower than the prior month and missed expectations, while imports rose by 8.3%, which was more than expected. In Europe, S&P reaffirmed at its AAA rating on Germany with a stable outlook. COMPANY NEWS: Target (TGT) shares slipped 1% after the company increased its estimate of people affected by its recent security breach to 70 million and said additional information may have been stolen. The company also cut its forecast for the fourth quarter performance of its U.S. unit, noting that it now expects same-store sales will fall about 2.5%, compared with a prior view that they would be flat compared to last year. Target stated that its new expectation reflects stronger-than-expected Q4 sales prior to the company’s announcement of its data breach and "meaningfully weaker-than expected" sales since the announcement... Another department store owner, Sears Holdings (SHLD), plunged 12% after forecasting worse than expected fourth quarter losses and saying domestic comparable store sales for the quarter-to-date fell 5.7% at Kmart and 9.2% at Sears stores in the U.S. MAJOR MOVERS: Among the notable gainers was Intercept Pharmaceuticals (ICPT), which rose another 70% after its stock nearly tripled yesterday following the company's trial of obeticholic acid for the treatment of non-alcoholic steatohepatitis being stopped early for efficacy. Also higher was SWS Group (SWS), which rose about 21% to $7.33 near midday after Hilltop Holdings (HTH) offered to buy the rest of SWS that it doesn't already own for $7 a share in cash and Hilltop stock. Hilltop shares also rose nearly 9% after making the proposal. Among the noteworthy losers was Chelsea Therapeutics (CHTP), which fell 29% after the FDA posted briefing documents related to a review of a resubmission for the company's Northera drug. Also lower were shares of trucker YRC Worldwide (YRCW), which declined 13% after members of the International Brotherhood of Teamsters did not approve the memorandum of understanding extension proposal made by the company. INDEXES: Near 1 pm ET, the Dow was down 35.43, or 0.22%, to 16,409.33, the Nasdaq was down 1.71, or 0.04%, to 4,154.49, and the S&P 500 was down 1.10, or 0.06%, to 1,837.03.
News For TGT;SHLD;ICPT;SWS;HTH;CHTP;YRCW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 15, 2015
13:47 EDTTGTTarget downgraded to Hold from Buy at Stifel
Subscribe for More Information
12:26 EDTTGTOn The Fly: Midday Wrap
Subscribe for More Information
11:58 EDTTGTTarget sees accelerating plans to expand CityTarget
Subscribe for More Information
11:46 EDTTGTTarget says Canada exit will allow quicker return to share repurchases
Subscribe for More Information
11:43 EDTTGTTarget says 'vast majority' of Canada exit costs are non-cash
Subscribe for More Information
10:35 EDTTGTTarget viewed unchanged after Canada exit, says RW Baird
Subscribe for More Information
10:22 EDTTGTTarget rallies after moving to close Canadian operations, levels to watch
Subscribe for More Information
10:12 EDTTGTTarget to host business news update conference call
Conference call to discuss Target Canada granted CCAA order will be held on January 15 at 11:30am. Webcast Link
10:04 EDTTGTTarget exit from Canada came sooner than expected, says Wells Fargo
Subscribe for More Information
09:46 EDTTGTTarget Canada granted CCAA order
Target announced that Target Canada has obtained an Initial Order from the Ontario Superior Court of Justice for creditor protection under the Companies' Creditors Arrangement Act, or CCAA, earlier this morning. The Initial Order authorizes Target Canada to begin a court-supervised wind-down of its Canadian businesses. It also provides for a broad stay of proceedings against Target Canada and authorizes Target to provide a debtor-in-possession credit facility of $175M to finance Target Canada’s operations during the CCAA proceedings. Note that Target announced earlier that it has decided to discontinue operations in Canada.
09:15 EDTTGTOn The Fly: Pre-market Movers
Subscribe for More Information
08:41 EDTTGTTarget raises Q4 adjusted EPS view to $1.43-$1.47, may not compare to $1.21
Based on performance through November and December, Target now expects to report Q4 U.S. comparable sales of approximately 3%, better than prior guidance of approximately 2%, driven primarily by increased traffic and stronger-than-expected digital sales. Sees Q4 adjusted EPS, reflecting results from continuing operations, of $1.43-$1.47, about 6c ahead of expectations for U.S. Segment performance at the beginning of the quarter. The company is not able to provide an estimate of its expected Q4 GAAP EPS. However, GAAP results are expected to include: Losses related to liquidation of Target Canada,net of taxes; Net expenses related to the 2013 data breach, which are not expected to be material; the impact of the reduction of the beneficial interest asset recognized in connection with the 2013 sale of the company’s credit card portfolio, which is expected to reduce GAAP EPS by approximately 2c.
08:28 EDTTGTTarget to report Canadian operations as discontinued starting in Q4
As a result of the Canada decision, Target Corporation will operate as a single segment that includes all U.S. operations. Beginning with the company’s Q4 financial results, Target will report adjusted earnings per share reflecting operating results from its U.S. operations, excluding discontinued Canadian operations, the impact of the reduction of the beneficial interest asset recognized in connection with the 2013 sale of the Company’s U.S. consumer credit card portfolio, net expenses related to the 2013 data breach, and the resolution of certain tax matters.
08:27 EDTTGTTarget to exit Canadian operations, sees move raising earnings in FY15 and after
Subscribe for More Information
08:24 EDTTGTTarget volatility flat into discontinuation of Canadian operations
Subscribe for More Information
08:23 EDTTGTTarget jumps after announcing plans to exit Canadian operations
Subscribe for More Information
08:21 EDTTGTTarget sees reporting $5.4B pre-tax losses on discontinued operations in Q4
08:19 EDTTGTTarget to discontinue Canadian operations
Subscribe for More Information
January 12, 2015
08:13 EDTICPTIntercept plans to initiate PSC Program Biliary Atresia Phase in 2H15
Intercept provided a clinical update on obeticholic acid, or OCA, a novel bile acid analog and first-in-class agonist of the farnesoid X receptor, or FXR, as well as planned 2015 milestones and other general business updates. OCA is currently being developed for the treatment of several chronic liver diseases, including primary biliary cirrhosis, or PBC, nonalcoholic steatohepatitis, or NASH, and primary sclerosing cholangitis, or PSC. The completion of PBC Program NDA and MAA filings planned in 1H15. The NASH Program Phase 3 program initiation planned in 1H15 and Japan Phase 2 trial data expected at the end of 2015. The PSC Program Biliary Atresia: Phase 2 initiation planned in 2H15 and INT-767: Phase 1 initiation planned for the end of 2015. Intercept ended 2014 with approximately $240M in cash and investments. For FY15, the company projects adjusted operating expenses in the range of $180M-$200M, which excludes stock-based compensation and other non-cash items. These expenses will support the clinical development program for OCA in PBC, NASH and PSC, expansion of our clinical, regulatory, medical affairs and commercial infrastructure in the United States and Europe, expansion of OCA manufacturing activities, as well as advancement of INT-767 and other preclinical pipeline programs. Adjusted operating expense, as presented above, is a non-GAAP financial measure. The company anticipates that stock-based compensation expense will represent the most significant non-cash item that is excluded in adjusted operating expenses as compared to operating expenses under GAAP.
06:35 EDTSHLDObama to press for law requiring disclosure of hacking, NY Times says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use